trans-2-Heptenal

We are trans-2-Heptenal CAS:18829-55-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:trans-2-Heptenal
CAS.NO:18829-55-5
Synonyms:trans-2-Heptenal
2-trans-heptenal
trans-hept-2-en-1-al
(E)-Hept-2-enal
 
Physical and Chemical Properties:
Density 0.8±0.1 g/cm3
Boiling Point 166.0±0.0 °C at 760 mmHg
Molecular Formula C7H12O
Molecular Weight 112.170
Flash Point 53.3±0.0 °C
 
Specification:
Appearance:Colorless to pale yellow liquid
Assay:≥99.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Flavors and fragrances intermediate

trans-2-Heptenal


Related News: The risk-based score generated by the tool helps sponsors gain advance understanding of the appropriate level of clinical supply management oversight needed to help get their project started on time and maintain momentum as the study progresses.1-cloro-8-broMooctano CAS:28598-82-5 The risk-based score generated by the tool helps sponsors gain advance understanding of the appropriate level of clinical supply management oversight needed to help get their project started on time and maintain momentum as the study progresses.3158-91-6 Optimize the reaction and improve the production process to reduce the production cost. At the same time, strengthen the determination and analysis of impurities to improve product quality.2-Methyl-2-propanyl 4-(6-{[8-cyclopentyl-5-methyl-7-oxo-6-(1-prop oxyvinyl)-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino}-3-pyridin yl)-1-piperazinecarboxylate CAS:866084-31-3 By drawing these distinctions between APIs and the drugs themselves, manufacturers are able to specialize and pharmacists able to align generic equivalents with brand names.Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).

Related Products
Product Name
2,2′-dibromo-9,9′-spirobi[fluorene] View Details
Fmoc-D-Arg(pbf)-OH View Details
(S)-(-)-3-(Benzoylthio)-2-methylpropanoic acid View Details
1-butyl-2,3-dimethylimidazolium tetrafluoroborate manufacturer 7-methoxy-6-(3-morpholin-4-ylpropoxy)-1H-quinazolin-4-one manufacturer 2-Bromo-5-methoxypyridine manufacturer 2-Amino-6-bromobenzoic acid manufacturer N-[[(1,1-Dimethylethyl)Amino]Carbonyl]-3-Methyl-L-Valine manufacturer